It's time to screen routinely for 22q11.2 deletion syndrome: new evidence of improved outcomes with prenatal diagnosis

March 13, 2024

To manage pregnancies at high risk for 22q11.2 deletion syndrome (DS), prenatal and neonatal evaluation after high risk cfDNA screening is needed. Supplemental assessments and early intervention can improve outcomes in patients with cardiac anomalies, hypocalcemia, cleft palate, kidney disease, intellectual development, and schizophrenia. This webinar will review recent publications with findings that add to what is known about the diagnosis and management of 22q DS in routine practice.

It's time to screen routinely for 22q11.2 deletion syndrome: new evidence of improved outcomes with prenatal diagnosis

Maternal health matters: findings from prenatal genetic screening with implications beyond pregnancy care

New Comprehensive Carrier Screening with Horizon Webinar

New Comprehensive Carrier Screening with Horizon Webinar - Condensed

Carrier Manifestations in Pregnancy

Empower Glossary*

Impact of high‐risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from t

Natera Product Brochure

Validation of an Enhanced Version of a Single- Nucleotide Polymorphism-Based Noninvasive Prenatal Test for Detection of Fetal Aneuploidies

Informatics-based, highly accurate, noninvasive prenatal paternity testing

Letter to the Editor by Megan Hall in response to Munne S.

Detection of triploid, molar, and vanishing twin pregnancies by a single-nucleotide polymorphismebased noninvasive prenatal test

Validation of a Single-Nucleotide Polymorphism-Based Non-Invasive Prenatal Test in Twin Gestations: Determination of Zygosity, Individual Fe

De novo HRAS gene mutation associated with Costello syndrome identified by non-invasive cell-free fetal DNA screening

Re: Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate

Estimating the relative frequency of leukodystrophies and recommendations for carrier screening in the era of next-generation sequencing

Primary cell-free DNA screening or contingent screening for the common trisomies: a response

Performance of noninvasive prenatal screening for 22q11.2 deletion syndrome in the SMART study

Introduction to Genetic Counseling Roles in Industry

Patient Medical Records Release Form (Rev 6 - Sept 2023)

Duchenne Muscular Dystrophy: Impact of carrier screening for reproductive risk and pregnancy management Direct